arrow
A

Ambrogio Orlando

villa sofia-cervello hospital
H指数:44
被引数:8,252

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A propensity score weighted comparison of intravenous and subcutaneous infliximab as maintenance treatment in patients with inflammatory bowel disease: The CISI study

炎症性肠病患者维持治疗中静脉注射与皮下注射英夫利昔单抗的倾向性评分加权比较:CISI研究

2026-11-020
PRE
Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

美基珠单抗在溃疡性结肠炎中的诱导和延长诱导治疗——来自西西里炎症性肠病网络(SN-IBD)的前瞻性真实世界研究

2026-07-300
OAAI
Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care (vol 25, 104068, 2026)

炎症性肠病中的动态特征分析:个性化护理的宣言(卷 25,104068,2026)

2026-06-010
OAAI
Performance of GPT-5 in the Interpretation of IBD Histopathology Reports
2025-12-010
OAAI
Inflammatory Bowel Disease Patients with a History of Cancer: Safety of Immunomodulators in a Multicenter Study

炎症性肠病患者中的癌症病史患者:免疫调节剂在多中心研究中的安全性

2025-10-110
OAAI
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study

对于接受静脉注射 Vedolizumab 诱导治疗后出现部分应答的炎症性肠病患者,转为皮下给药可能比强化静脉治疗带来更深的缓解:PRIVEDO 研究

2025-10-010
PRE
The Role of Imaging in Inflammatory Bowel Diseases: From Diagnosis to Individualized Therapy

炎症性肠病中影像学的作用:从诊断到个体化治疗

2025-09-290
OAAI
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study

托法替尼与菲戈替尼在溃疡性结肠炎患者中的比较疗效与安全性:一项倾向性评分加权队列研究

2025-08-260
PRE
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD)

托法替尼治疗溃疡性结肠炎相关脊柱关节病的真实世界有效性:一项来自意大利炎症性肠病研究小组(IG-IBD)的多中心前瞻性研究

2025-08-250
OA
IBD impact on quality of life and perception of disease activity in Italian patients and physicians: An IBD-PODCAST study sub analysis

IBD对意大利患者和医生生活质量及疾病活动度感知的影响:IBD-PODCAST研究的子分析

2025-06-140
OAAI
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study

Vedolizumab在炎症性肠病中的真实世界结局及其机器学习预测——IG-IBD LIVE研究

2025-05-120
PRE
Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study
2025-03-010
OAAI
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy (RETUCAS): a Multicentre Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD)
2025-01-220
PRE
Learning Curve in Intestinal Ultrasound: Advancing from Basic Skills to Advanced Competencies - Insights from the IUS IG-IBD (Italian Group for the Study of Inflammatory Bowel Disease) Master Program
2025-01-220
PRE
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study
2025-01-010
OAAI